Who are GamEvac-Combi (vaccine)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DTacP-IPV combined vaccine (TETRAXIM™).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gamevac-combi-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

GamEvac-Combi (vaccine) — Competitive Intelligence Brief

GamEvac-Combi (vaccine) (GamEvac-Combi (vaccine)) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination inactivated vaccine. Area: Immunology / Infectious Disease.

marketed Combination inactivated vaccine Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

GamEvac-Combi (vaccine) (GamEvac-Combi (vaccine)) — Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation. GamEvac-Combi is a combination vaccine that stimulates immune responses against tick-borne encephalitis and Lyme disease through viral antigens.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
GamEvac-Combi (vaccine) TARGET	GamEvac-Combi (vaccine)	Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation	marketed	Combination inactivated vaccine
DTacP-IPV combined vaccine (TETRAXIM™)	DTacP-IPV combined vaccine (TETRAXIM™)	Sanofi	marketed	Combination inactivated vaccine	Diphtheria toxin, tetanus toxin, Bordetella pertussis antigens (PT, FHA, PRN), poliovirus types 1, 2, and 3

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination inactivated vaccine class)

Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation · 1 drug in this class
Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GamEvac-Combi (vaccine) — Competitive Intelligence Brief. https://druglandscape.com/ci/gamevac-combi-vaccine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab